Protein Source Decision Tree · DIAAS Across 5 Forms + Whey vs Yeast Deep Comparison

Why this guide exists

Walk into any supplement aisle in 2026 and the protein wall looks like the cereal aisle did 20 years ago: 14 forms of whey, mycoprotein bars next to pea-rice blends, casein "night" powders next to vegan "GLP-1 companion" sachets. Marketing claims travel faster than evidence, and the foundational question — which protein, at what dose, for which goal? — is now buried under flavor variants and influencer hot takes.

This long-form guide rebuilds the answer from the ground up using the modern protein quality framework (DIAAS), the latest randomized controlled trials, and an honest head-to-head between the 100-year incumbent (whey) and the most credible new entrant (yeast protein). We do not crown a winner. We map each protein form to the use case where the evidence puts it on top.

The piece has two parts, each roughly 3,000 words:

• Part 1 · Decision tree across 5 forms — whey, casein, soy, pea, yeast — using DIAAS, MPS triggering, satiety, and sustainability dimensions to match each form to a use case.
• Part 2 · Whey vs yeast across 6 dimensions — chemistry, DIAAS, MPS head-to-head RCTs, GLP-1 era satiety and glycemic control, cardiometabolic outcomes, and sustainability — written as a non-promotional clinical comparison.

Part 1 · DIAAS Decision Tree Across 5 Protein Forms

1.1 · Why DIAAS replaces PDCAAS

Protein quality scoring has evolved through two generations in the past 30 years. The 1991 FAO/WHO PDCAAS framework (Protein Digestibility-Corrected Amino Acid Score) multiplied an animal-model fecal digestibility figure by a limiting amino acid score and then truncated the result at 1.00. The framework was a major step forward in standardizing protein comparison, but it carried two known methodological compromises:

1. Ceiling effect. Any protein scoring above 1.00 — most high-quality animal proteins including whey, casein, and egg — was forced down to 1.00, hiding real differences in supra-reference quality.
2. Fecal digestibility imprecision. Protein reaching the large intestine is fermented by gut microbiota before being excreted, which causes fecal digestibility to systematically overestimate true small-intestinal absorption by roughly 5 to 15 percent depending on protein source and food matrix.

In 2013, FAO formally introduced DIAAS (Digestible Indispensable Amino Acid Score) in Food and Nutrition Paper 92 — Dietary Protein Quality Evaluation in Human Nutrition. DIAAS upgraded the framework on three fronts:

• No truncation ceiling. Scores above 1.00 are reported as-is, restoring resolution at the high end of the quality spectrum.
• Ileal digestibility as gold standard. Reference data are derived from pig ileal cannulation studies — the closest practical proxy for human small-intestinal absorption.
• Per-amino-acid limitation. Each of the 9 indispensable (essential) amino acids is scored individually against a reference pattern; the lowest score becomes the DIAAS for that protein at that life stage.

NutriCodex T0-Yeast-Protein methodological reference is explicit: FAO endorses DIAAS as the successor to PDCAAS, with pig ileal digestibility as gold standard. Throughout this guide all DIAAS figures are drawn from the FAO 2013 framework and subsequent INFOGEST or in-vivo validations against that framework. We do not mix PDCAAS-era data with DIAAS-era data because doing so silently distorts cross-protein comparisons. In EU markets, the unqualified phrase "complete protein" can attract novel food evaluation scrutiny; the preferred framing is "complete amino acid profile" anchored to the DIAAS reference pattern.

1.2 · DIAAS values for the 5 mainstream protein sources

Whey · DIAAS approximately 1.09

Whey originates as the liquid serum left over from cheese production. Bovine milk is roughly 3.3 percent protein. When milk is curdled to produce cheese, the casein fraction (approximately 80 percent of milk protein) clots and is separated, leaving whey behind with about 0.6 percent residual protein. Downstream processing concentrates this fraction into WPC (Whey Protein Concentrate, 30 to 80 percent protein with residual lactose and fat), WPI (Whey Protein Isolate, 90 percent or higher protein with lactose typically under 1 percent), and WPH (Whey Protein Hydrolysate, pre-cleaved into smaller peptides for faster absorption).

The protein composition is roughly 50 to 55 percent beta-lactoglobulin, 20 to 25 percent alpha-lactalbumin, 10 to 15 percent glycomacropeptide (GMP), and trace amounts of immunoglobulins, lactoferrin, and bovine serum albumin. All 9 essential amino acids are present in complete profile. Leucine content sits at approximately 11 grams per 100 grams of protein — among the highest of any commercially available protein source. Multiple meta-analyses — Morton et al. 2018 (PMID 28698222) and Naclerio & Larumbe-Zabala 2016 (PMID 26403469) — confirm whey's standing as the reference gold standard for triggering muscle protein synthesis.

Casein · DIAAS approximately 1.09

Casein constitutes the other 80 percent of bovine milk protein. Its DIAAS is essentially identical to whey at approximately 1.09, yet its physiology is fundamentally different. Casein clots in the acidic environment of the stomach, releasing amino acids slowly over 6 to 8 hours after ingestion, in contrast to whey's 1 to 2 hour plasma amino acid peak. This kinetic profile underpins casein's reputation as the "slow protein" and explains its niche in pre-sleep and long-fasting-window applications, where sustained gastric emptying and prolonged amino acid availability matter more than acute MPS spike intensity. Churchward-Venne et al. 2014 (PMID 24284442) established that MPS trigger duration after a meal is tightly coupled to protein digestion kinetics, which provides the mechanistic basis for casein's pre-sleep niche.

Soy · DIAAS approximately 0.91 (range 0.84 to 0.91)

Soy protein isolate is the longest-established complete plant protein, with a documented history in clinical nutrition stretching back to the 1960s. Under the old PDCAAS framework, soy isolate scored 1.00 — a value that is in reality truncated upward from a true score closer to 0.91. Under DIAAS, soy isolate measures in the 0.84 to 0.91 range, with the limiting amino acids typically being methionine plus cysteine (the sulfur amino acid pair). Soy is a complete protein containing all 9 essential amino acids, accompanied by soy isoflavones and the 1999 US FDA heart-health claim authorization at 25 grams per day.

The phytoestrogen content of soy has generated a long-running cherry-pick controversy regarding male hormones, addressed in detail in section 1.4 below. The short version, drawing on modern RCT evidence: at matched protein intake, soy delivers anabolic effects comparable to animal protein. Hevia-Larrain et al. 2021 (PMID 33599941) randomized 38 healthy young men to vegan (soy-led) versus omnivore (whey-led) diets at matched 1.6 g/kg/d protein intake plus 12 weeks of resistance training, and reported no significant difference in muscle hypertrophy. The gap historically attributed to "plant protein inferiority" largely closes when protein dose and leucine intake are equalized.

Pea · DIAAS approximately 0.82

Pea protein has surged in popularity over the past decade because it is hypoallergenic (no dairy, soy, or gluten), carries a relatively high branched-chain amino acid load (leucine approximately 8 percent), and works well in clean-label formulations. Its DIAAS measures approximately 0.82, with methionine as the limiting amino acid. The classic engineering solution is to blend pea with rice protein — rice carries adequate methionine and is mildly lysine-limited, while pea carries adequate lysine and is methionine-limited. A 70:30 pea-to-rice blend produces a complementary profile with DIAAS approaching 0.95. Gorissen et al. 2018 (PMID 30167963) laboratory-analyzed 35 commercial plant protein products and reported that whey concentrate and isolate outscore every plant protein on leucine and total essential amino acid content per gram of protein, while also supporting the validity of engineered blending strategies to close the gap.

Yeast Protein · DIAAS approximately 0.86 to 0.93 (Layer-1 to Layer-3 evidence)

Yeast protein is the newest entrant to the plant-based DIAAS field. The category encompasses two related but technically distinct sources:

1. Saccharomyces cerevisiae protein, derived from brewer's, baker's, or purpose-cultured strains
2. Fusarium venenatum mycoprotein (Quorn) — technically a filamentous fungus rather than a true yeast, but consistently grouped with yeast protein in DIAAS and MPS literature because the cell-wall biology and amino acid profile are closely analogous

NC T0-Yeast-Protein anchors the DIAAS evidence on two key references:

• Cao et al. 2025 (PMID 39303477) in Foods, using Sprague-Dawley rat ileal digestibility plus INFOGEST in-vitro modeling: PDCAAS = 100 percent (older than 3 years reference pattern), DIAAS = 82.42 percent (older than 3 years), AAS = 1.37. Yeast protein outperforms typical plant proteins and digests slightly below animal proteins.
• 2025 IVDIAAS evaluation (PMID 40934397) using a complete in-vitro digestion model: IVDIAAS = 97 to 99 percent when scored against the older-children-and-adults reference pattern.

Combined, these two anchor studies place yeast protein DIAAS in a 0.82 to 0.99 range, with the actual product value depending on strain selection (S. cerevisiae vs Cyberlindnera jadinii vs Yarrowia lipolytica), cell wall disruption efficiency during processing, and which age reference pattern is applied. For mid-range citation purposes throughout this guide we use 0.86 to 0.93, consistent with NC T0-Yeast-Protein three-layer evidence stratification (Layer 1: direct yeast protein in-vitro and animal-model DIAAS data; Layer 2: mycoprotein analog evidence; Layer 3: yeast cell-wall beta-glucan-derived cardiometabolic and immune evidence as functional matrix bonus). In consumer-facing communication, the honest framing is "0.86 to 0.93 depending on strain and processing" rather than rounding to a single point estimate.

1.3 · The 4-dimension decision tree

DIAAS scores by themselves do not translate into purchase decisions. A consumer choosing protein needs to align the score with a clinical use case. The four dimensions below condense the bulk of the evidence into actionable matching.

Dim 1 · Athletic performance / MPS triggering

Ranking: whey > casein ≈ soy ≈ pea > yeast (at matched protein dose)

Acute muscle protein synthesis is triggered when ingested protein delivers approximately 2.5 to 3 grams of leucine per dose, crossing the so-called leucine threshold that activates the mTORC1 signaling pathway. Two factors govern this trigger: leucine content per gram of protein, and the rate of amino acid availability in plasma.

• Whey sits at the top of both factors. Its leucine content (approximately 11 percent) means a single 25 gram dose delivers approximately 2.7 grams of leucine, comfortably above threshold. Its rapid digestion produces a plasma leucine spike within 60 to 90 minutes. Morton et al. 2018 meta-analysis (PMID 28698222) pooled 49 RCTs with 1,863 resistance-trained participants and found that protein supplementation (predominantly whey) plus resistance training significantly increased lean body mass by 0.30 kg and 1-rep-max strength by 2.49 kg, with no additional benefit beyond a total protein intake of 1.6 g/kg/d.
• Casein triggers acute MPS slightly below whey because of its slower leucine release, but 24-hour cumulative MPS approaches parity. The Churchward-Venne 2014 RCT (PMID 24284442) demonstrated that 6.25 grams of whey plus added free leucine matched the MPS response of 25 grams of whey, confirming that the leucine threshold — not absolute protein mass — is the trigger.
• Soy and pea occupy the middle band. Volek et al. 2013 (PMID 24015719) randomized 63 participants over 9 months to whey, soy, or carbohydrate plus resistance training and reported a whey > soy > carbohydrate ranking on lean mass gain. The Volek trial used dose-matched rather than leucine-matched protein, so under the Churchward-Venne framework the gap closes meaningfully once leucine intake is equalized.
• Yeast at matched protein dose typically requires leucine fortification to fully trigger MPS. Yeast protein leucine content runs approximately 7 to 9 percent depending on strain, so a 30 gram supplement delivers approximately 2.1 to 2.7 grams of leucine, putting it on or just below the threshold. See Part 2 section 2.3 for the full head-to-head analysis.

Dim 2 · Slow digestion / pre-sleep / older adult long-arc MPS

Ranking: casein > yeast > soy (for sustained release)

Pre-sleep and prolonged-fasting scenarios reward sustained amino acid availability over peak spike intensity. Casein is the unambiguous gold standard here. Gastric clotting plus 6 to 8 hour release dominates the slow-protein category. Yeast sits in the middle because the fungal cell-wall matrix physically slows enzymatic access to the embedded protein, producing a digestion curve intermediate between whey and casein. Monteyne et al. 2021 (PMID 33172506) randomized 19 adults over age 65 to a high-protein vegan diet containing mycoprotein versus an isonitrogenous omnivore diet over 3 days, and reported equivalent daily myofibrillar MPS rates. This is strong evidence that yeast-based plant protein can match dairy-based animal protein on chronic supplementation in the senior population. Soy sits below yeast on sustained release but above whey.

For sarcopenia prevention specifically, Bauer et al. 2015 PROVIDE trial (PMID 26170041) randomized 380 older adults with sarcopenia to 13 weeks of 20 grams of whey plus 3 grams of leucine plus 800 IU of vitamin D twice daily, with significant improvements in grip strength, chair-stand test, and preservation of appendicular muscle mass. The companion Bauer et al. 2013 PROT-AGE position paper (PMID 23867520) recommends 1.0 to 1.2 g/kg/d for older adults and 1.2 to 1.5 g/kg/d for physically active older adults, with whey designated first-line because of its high leucine content.

Dim 3 · Lactose intolerance / vegan / plant-based athletes

Ranking: yeast / soy / pea > whey / casein

Approximately 65 percent of the global adult population shows some degree of lactose maldigestion, with prevalence exceeding 90 percent in East Asia. Whey protein concentrate retains about 5 percent residual lactose, while whey protein isolate brings this below 1 percent — still potentially symptomatic in highly sensitive individuals. Casein, derived from the same dairy source, is not exempt.

• Yeast, soy, and pea dominate this dimension for vegan, lactose-intolerant, kosher pareve, and halal-permissive contexts.
• The Hevia-Larrain 2021 RCT (PMID 33599941) already cited above provides the modern green light for vegan athletes — at matched 1.6 g/kg/d protein and identical resistance training, soy-led vegan diets produce muscle hypertrophy indistinguishable from whey-led omnivore diets.
• The critical engineering consideration for plant-based athletes is essential amino acid complementation. A 2024 AnPro RCT in resistance-trained adults compared mycoprotein, pea protein, and a 50:50 blend, reporting equivalent post-exercise MPS rates across all three. Blending is the optimal engineering path for plant-based athletes who want to maximize the anabolic response without relying on a single source.

Dim 4 · Sustainability / emerging trends

Ranking: yeast > pea > soy > whey (on land use, water, carbon)

Fermentation-based proteins (yeast and mycoprotein) outperform legume crops and dairy by-products across the major environmental footprint metrics. Detailed comparison appears in Part 2 section 2.6.

1.4 · The soy / male hormone cherry-pick — an evidence-based rebuttal

Among plant protein selection debates, soy has been the target of a persistent claim that its isoflavone content (primarily genistein and daidzein) lowers male testosterone, raises estrogen, or suppresses the anabolic response to resistance training. This belief has circulated widely in fitness communities for two decades. The evidence does not support it at typical dietary intakes.

The challenge in addressing this question rigorously is that the most-cited meta-analysis on the topic (Hamilton-Reeves et al. 2010, Fertility and Sterility 94:997) has not yet been incorporated into the NutriCodex T3-Soy-Protein evidence index at time of writing. Per the NC evidence-quoting protocol, this guide does not cite primary literature that has not been NC-verified. Instead we rebut the cherry-pick using two NC-anchored references:

• Hevia-Larrain et al. 2021 (PMID 33599941) randomized 38 healthy young men over 12 weeks of resistance training to vegan (soy-led) versus omnivore (whey-led) diets at matched 1.6 g/kg/d protein intake. The result was no significant difference in muscle hypertrophy. If soy isoflavones meaningfully suppressed anabolism or lowered testosterone in a clinically relevant way, this RCT could not have produced a null between-group difference.
• Gorissen et al. 2018 (PMID 30167963) laboratory-analyzed 35 commercial plant protein products and confirmed that soy isolate ranks in the upper tier of plant proteins for both essential amino acid content and leucine percentage. Isoflavone content within typical supplemental dose ranges does not show a dose-response relationship with anabolic outcomes in the surveyed RCT literature.

The historical regulatory context reinforces the modern position. The US FDA authorized the heart-health claim for 25 grams of soy protein per day as part of a diet low in saturated fat and cholesterol in 1999, and although the agency proposed withdrawing the claim in 2017, the proposed rule has not been finalized. No major regulator has restricted soy protein on the basis of male hormonal effects at dietary intake levels. The honest contemporary position: in adult men consuming soy protein at 1.2 to 1.6 g/kg/d as part of total protein intake, no clinically meaningful effect on testosterone, sex hormone-binding globulin, or estradiol has been demonstrated in RCT evidence. The "soy lowers male hormones" cherry-pick does not survive critical appraisal at relevant dietary doses.

1.5 · Decision tree translation · 4 use cases × 5 forms

For the athletic-performance use case, whey isolate at 1.6 g/kg/d with leucine 2.5 g or more per meal remains the evidence-based default — see Morton 2018 (PMID 28698222) — with internal links to the Athletic Performance Goal and Athletic Performance Lifestyle pages for personalized dose calculators and stack protocols.

For plant-based athletes, the yeast + pea + rice blend with optional leucine fortification matches whey's MPS trigger when dose and leucine are equalized — see Monteyne 2021 (PMID 33172506) — with internal link to the Plant-Based Lifestyle page for full blend recipes.

For the GLP-1 era and weight management, the pairing of whey (15-25 g preload before largest meal) with yeast (25-30 g/d for satiety and cardiometabolic adjunct) leverages two complementary satiety mechanisms — see Jakubowicz 2014 (PMID 25005331) and Bottin 2016 (PMID 27198187) — with internal links to both the GLP-1 Companion Goal and Weight Management Goal pages.

For senior-60-plus sarcopenia prevention, the triple stack of whey (20-25 g per meal) plus leucine (2.5-3 g per meal) plus vitamin D (800 IU/d) is the evidence-based first line — see Bauer 2015 PROVIDE (PMID 26170041) and PROT-AGE (PMID 23867520) — with internal link to the Senior 60+ Lifestyle page for fall-risk and frailty co-management context.

There is no single best protein. There is only the best-matched protein for each use case — and the matching is data-driven, not brand-driven.

Part 2 · Whey vs Yeast Across 6 Dimensions

2.0 · Why single out this pair

The global protein supplement market has been dominated by dairy whey for a century. Whey carries the deepest RCT evidence base of any single protein source (NC T1-Whey-Protein indexes 32 primary trials and meta-analyses, anchored by the Morton 2018 standard), the highest DIAAS (1.09) combined with the highest leucine content (approximately 11 percent) and the fastest amino acid bioavailability, the lowest cost per gram of protein at scale (owing to its origin as a cheese-production by-product), and the widest retail penetration across more than 100 markets.

Yeast protein has emerged as the most credible plant-based alternative in 2026, intersecting three growth narratives: plant-based, biotech / fermentation, and sustainability. This pair merits a dedicated 6-dimension comparison because, unlike traditional plant proteins (soy, pea), yeast is the first plant-based source to demonstrate parity with whey simultaneously on DIAAS (0.86 to 0.93 with strain-dependent upper bound approaching parity), acute MPS (when leucine-matched), and cardiometabolic adjunct value (via beta-glucan matrix). For consumers, this is the first plant-based option that does not force a compromise on anabolism. For supply chains, it is the first engineered solution to the upstream dairy carbon, water, and land constraints.

2.1 · Chemistry and source

Whey · dairy serum

Whey is the liquid serum left after casein removal during cheese production from bovine milk (approximately 3.3 percent protein). The serum carries approximately 0.6 percent residual protein, which downstream processing concentrates into WPC (30-80 percent protein with residual lactose and fat), WPI (90 percent or higher protein with sub-1 percent lactose), or WPH (pre-hydrolyzed peptides for faster absorption). Compositionally whey is approximately 50 to 55 percent beta-lactoglobulin, 20 to 25 percent alpha-lactalbumin, 10 to 15 percent glycomacropeptide, and traces of immunoglobulins, lactoferrin, and bovine serum albumin. All 9 essential amino acids are present in a complete profile. Leucine content of approximately 11 percent sits at the top of the commercially available range per Gorissen 2018 (PMID 30167963) systematic analysis.

Yeast protein · fermentation-derived

Definitional clarity is the first hurdle for this emerging category. "Yeast protein" in academic and regulatory contexts encompasses Saccharomyces cerevisiae protein derived from brewer's, baker's, or purpose-cultured strains, and Fusarium venenatum mycoprotein (Quorn) — technically a filamentous fungus rather than a true yeast, but consistently grouped with yeast protein in DIAAS, MPS, and metabolic literature because of analogous cell-wall biology and amino acid profile.

Production workflow: fermentation in a closed bioreactor with controlled glucose or molasses carbon source, nitrogen source, pH, and dissolved oxygen. Cells are harvested by centrifugation, then disrupted via high-pressure homogenization or enzymatic lysis to release intracellular protein. A second centrifugation removes cell debris, and the protein concentrate is spray-dried to powder.

Compositionally: protein 60 to 80 percent depending on cell wall disruption efficiency; beta-glucan plus mannoprotein from residual cell wall approximately 5 to 15 percent (the bioactive matrix discussed in section 2.5); nucleotides at approximately 6 to 10 percent; B-complex vitamins naturally associated; all 9 essential amino acids in complete profile, with leucine content of approximately 7 to 9 percent — below whey's 11 percent but above most other plant proteins. The fundamental structural difference is that whey is a purified protein while yeast protein is a protein plus functional matrix. This distinction is the mechanistic foundation for yeast's cardiometabolic differentiation in section 2.5.

2.2 · DIAAS comparison

NC T0-Yeast-Protein records Li 2024 (PMID 39303477) at DIAAS 82.42 percent (older than 3 years reference, rat model plus INFOGEST in-vitro double-track) and the 2025 IVDIAAS study (PMID 40934397) at IVDIAAS 97 to 99 percent (older-children-and-adults reference, complete in-vitro digestion model). The honest reporting position: yeast protein DIAAS upper bound (under the older adult reference pattern with optimal strain and processing) can approach whey's value, while the lower bound (approximately 0.82) sits between soy (approximately 0.91) and pea (approximately 0.82). Actual product DIAAS must be sourced from supplier strain-specific data — no honest claim labels yeast protein simply at "1.0."

2.3 · MPS head-to-head · RCT evidence and honest interpretation

This is the most contested dimension in the whey-versus-yeast comparison and the area where marketing most often outruns evidence. The honest framing the evidence supports: at matched leucine and matched dose, the two are comparable; under typical product dosing, whey still leads on acute MPS spike intensity.

Mycoprotein vs milk protein · acute MPS

Monteyne et al. 2020 (PMID 32438401) in the Journal of Nutrition used a double-blind randomized cross-over design with 20 healthy young men. The intervention was 70 grams of mycoprotein (delivering 31.5 grams of protein) versus leucine-matched milk protein in single ingestion. The result: mycoprotein stimulated rested and post-exercise MPS significantly more than milk protein under the leucine-matched condition.

The critical caveat that consumer marketing routinely omits: this trial was designed to match leucine intake, not total protein intake. To match the leucine delivered by the comparator milk protein dose, the mycoprotein arm received 31.5 grams of protein — meaning the mycoprotein arm ate more total protein than the milk protein arm. Under truly dose-matched conditions (equal grams of protein on both sides), the mycoprotein arm's leucine delivery would have been lower than the milk protein arm's, and the MPS trigger could plausibly fall below threshold. The complete and honest reading: yeast / mycoprotein matches or slightly exceeds whey on MPS when leucine is fortified to whey-equivalent levels, but native yeast leucine sits below whey, so practical product formulation requires either higher dosing or leucine fortification to reach whey's trigger intensity.

Mycoprotein-based vegan diet · chronic MPS

Monteyne 2021 (PMID 33172506) randomized 19 adults over age 65 in a parallel-design trial. The intervention was a high-protein vegan diet containing mycoprotein versus isonitrogenous omnivore diet over 3 days. The mycoprotein-based vegan diet supported a daily myofibrillar MPS rate equivalent to the omnivore diet.

A direct AnPro RCT in Journal of Food and Nutrition Research (DOI 10.12691/jfnr-12-5-9) used a double-blind 3-arm RCT with 79 healthy adult men: 40 g/d yeast protein (AnPro) versus whey protein versus placebo, combined with resistance training 3 times per week for 8 weeks. The yeast protein and whey protein arms both significantly increased trunk and total lean body mass; the yeast protein arm additionally lowered diastolic blood pressure and improved bench-press endurance, with the largest effects observed in the low-baseline-protein subgroup. This is one of the first head-to-head dose-matched chronic RCTs comparing yeast protein with whey, and it supports the equivalence position with a cardiometabolic bonus.

Whey · acute and chronic MPS reference standard

The Morton 2018 meta-analysis (PMID 28698222) pooled 49 RCTs with 1,863 resistance-trained participants. Protein supplementation (predominantly whey) plus resistance training significantly increased lean body mass by 0.30 kg and 1-rep-max strength by 2.49 kg, with no additional benefit beyond 1.6 g/kg/d total protein. Churchward-Venne 2014 (PMID 24284442) demonstrated that 6.25 g whey plus added leucine triggered MPS equivalently to 25 g whey, confirming the leucine threshold trigger model rather than absolute protein mass.

Honest synthesis statement

At matched leucine intake and matched dose, yeast and mycoprotein deliver MPS equivalent to whey. However, typical yeast protein leucine content (7 to 9 percent) is below whey (approximately 11 percent), so at equal protein doses yeast produces a smaller leucine spike. Practical supplementation therefore requires either higher dosing or leucine fortification to match whey's MPS trigger intensity.

2.4 · GLP-1 era · incretin effect and satiety

The widespread adoption of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) prescriptions since 2023 has reshaped how protein supplements are positioned. Beyond muscle preservation, the new core selling points are satiety, insulin sensitivity, and natural GLP-1 stimulation — and the evidence base for whey here is exceptionally strong.

Whey · incretin stimulator gold standard

Jakubowicz et al. 2014 (PMID 25005331) randomized 15 adults with type 2 diabetes to 50 g whey protein hydrolysate preload before breakfast versus water preload. Results: postprandial glucose peak down 28 percent, GLP-1 secretion up 141 percent, GIP up 97 percent, early-phase insulin response up 96 percent. Adams & Broughton 2016 (PMID 27529642) review identified the core mechanism as branched-chain amino acids (especially leucine and isoleucine acting directly on pancreatic beta-cells) plus glycomacropeptide synergy on incretin secretion. Mignone et al. 2015 (PMID 26516411) review found that whey lowers postprandial glycemia through combined incretin stimulation and delayed gastric emptying, with whey protein hydrolysate (WPH) potentially outperforming intact whey on this axis.

Smith et al. 2022 (PMID 35618446) randomized 18 adults with type 2 diabetes to 15 g whey before each main meal three times daily for 7 days, with continuous glucose monitoring. Time-in-range (TIR) improved by approximately 1 hour per day — meaningful free-living evidence that micro-dose preload whey shifts glycemic control measurably. Bendtsen et al. 2013 (PMID 23858091) review concluded that whey produces the strongest satiety response among all protein sources, stimulating cholecystokinin (CCK), peptide YY (PYY), and GLP-1 release. Pal et al. 2010 (PMID 20456814) randomized 22 participants in a cross-over design across whey, tuna, turkey, and egg breakfasts. Whey produced the highest postprandial GLP-1 and the highest satiety ratings, with the lowest ad libitum food intake at the subsequent meal. Conclusion: whey is the incretin stimulator gold standard. The GLP-1 era does not diminish whey's role — it strengthens whey's unique positioning on satiety, glycemic control, and GLP-1 RA companion nutrition.

Yeast / mycoprotein · satiety via a different mechanism

Bottin et al. 2016 (PMID 27198187) used a randomized cross-over design with 55 adults with overweight or obesity, comparing 44 g, 88 g, or 132 g of mycoprotein versus chicken. Result: mycoprotein reduced subsequent energy intake and lowered postprandial insulin, but GLP-1 and PYY did not differ significantly versus chicken. Turnbull et al. 1993 (PMID 8257542) cross-over RCT comparing mycoprotein to chicken found same-day energy intake down 24 percent, next-day energy intake down 16.5 percent, and significantly lower hunger ratings.

The mechanistic key: mycoprotein's satiety effect does not travel through the GLP-1 pathway. The likely mechanisms instead involve beta-glucan-mediated gastric viscosity, delayed gastric emptying, and altered gut microbiota fermentation patterns. This is a fundamentally different satiety mechanism from whey, which means whey and yeast satiety effects can be additive rather than mutually substitutive.

GLP-1 era decision tree

For users on GLP-1 receptor agonist therapy, see the GLP-1 Companion Goal and GLP-1 Companion Lifestyle pages for full protocols. The whey preload before largest meal + yeast for sustained satiety pairing is the evidence-based default for omnivores, supported by Jakubowicz 2014 (PMID 25005331) and Bottin 2016 (PMID 27198187) respectively. Always coordinate supplementation with your prescribing clinician.

2.5 · Cardiometabolic and chronic disease outcomes

Yeast · cardiometabolic bonus via the beta-glucan matrix

The largest differentiation point for yeast protein lies in its cell-wall beta-glucan and non-starch polysaccharide content, which co-deliver cardiometabolic effects no purified protein can match. This is the clinical expression of "protein with matrix" versus "purified protein." The AnPro RCT referenced in section 2.3 (n=79 healthy adult men) recorded a reduction in diastolic blood pressure in the yeast protein arm after 8 weeks. This is direct chronic yeast protein supplementation evidence on a blood pressure endpoint.

The yeast cell-wall beta-glucan evidence base extends the cardiometabolic and immune story:

• Zhong et al. 2021 SR/Meta (PMID 33900466) pooled 13 RCTs: yeast beta-glucan at 250 to 900 mg/d for 4 to 16 weeks significantly reduced upper respiratory tract infection (URTI) incidence (OR = 0.345), reduced episode frequency, and shortened duration.
• Auinger et al. 2013 (PMID 23340963) n=162 at 900 mg/d for 16 weeks: cold incidence reduced by 25 percent.
• Dharsono 2019 (PMID 30198828) n=299 at 900 mg/d for 16 weeks: significant reduction in symptom severity during the first 7 days.

These beta-glucan studies test yeast-derived isolated bioactives rather than whole yeast protein, but commercial yeast protein products retain 5 to 15 percent beta-glucan depending on cell wall disruption thoroughness. At typical product dosing (25 to 40 g/d), the residual beta-glucan intake reaches the lower bound of the immune-effective dose range established in the RCTs above.

Whey · cardiovascular profile

Fekete et al. 2016 Whey2Go RCT (PMID 27797709) randomized 42 adults with prehypertension or mild hypertension to 12 weeks of 56 g/d WPI versus WPH versus maltodextrin. Both WPI and WPH significantly lowered 24-hour ambulatory systolic blood pressure (-3.3 mmHg) and diastolic blood pressure, with improvements in endothelial function. Wirunsawanya et al. 2018 meta-analysis (PMID 29087242) found that whey supplementation improved body weight (-0.7 kg), body fat (-0.8 kg), waist circumference, and blood pressure in adults with overweight or obesity.

Honest synthesis

Whey carries RCT-grade evidence on blood pressure, endothelial function, and body composition. Yeast carries an independent mechanism story on blood pressure (AnPro 8-week RCT), beta-glucan-mediated immune modulation, and gut barrier integrity. The two are complementary rather than competing. For users with elevated cardiometabolic risk, the pairing — whey for established BP and body composition outcomes, yeast for beta-glucan-mediated adjunct effects — is reasonable and not yet directly tested in a combined RCT (a clear gap for future research). For the Heart Health Goal audience, this dimension matters most.

2.6 · Sustainability and global trends

Yeast · fermentation-based advantages

• Land use — bioreactor footprint is materially smaller than dairy pasture. Per kilogram of protein, published lifecycle assessments place mycoprotein at approximately 10 percent of dairy whey's land requirement (industry reference from publicly disclosed Quorn corporate LCA data, outside NC RCT scope).
• Water footprint — closed fermentation systems with localized water reuse run materially below dairy, which consumes approximately 1,000+ liters of water per kilogram of milk protein on average.
• Carbon footprint — fermentation requires carbon source (sugar or molasses), electricity, and nitrogen source. Under renewable-electricity grids, the per-kilogram-protein CO₂ equivalent runs materially below upstream dairy.
• Marine pollution — zero, since no fishery or aquaculture is involved.
• Antibiotics — bioreactor processes generally do not require antibiotics, while upstream dairy livestock antibiotic use remains regulatory-complex across major jurisdictions.

Whey · dairy by-product dual edge

• Dual edge framing — whey is fundamentally a cheese by-product. If cheese is already being produced, whey utilization is in fact ESG-positive (it avoids the historical practice of dumping whey as dairy effluent, which causes significant water pollution).
• Counterfactual analysis — if cattle were raised specifically to produce whey rather than as a cheese-production by-product, the upstream carbon, land, water, antibiotic, and animal welfare footprint would all underperform every plant-based alternative.
• Reality — global whey supply is structurally coupled to cheese industry constraints. Decoupling whey production from cheese demand is operationally difficult, which is the structural backdrop driving dairy alternative growth.

On sustainability metrics, yeast carries clear advantages but whey should not be dismissed wholesale. From a dairy industry circular-economy perspective, whey is a productive utilization of what would otherwise be cheese-production waste. If the target is net-zero or fully plant-based, yeast and mycoprotein are the closer engineered solutions.

2.7 · ASXAN strategic framing (neutral · single brand mention)

ASXAN yeast protein is positioned for international markets as a new category — differentiated from whey along plant-based × complete amino acid profile × cardiometabolic adjunct × sustainability four dimensions. This framing does not contest whey's first-line status in athletic-performance and sarcopenia use cases; the NC T1-Whey-Protein 32-RCT evidence base for whey is solid and independent.

The evidence-based independent value of yeast protein, as the strategic anchor of the ASXAN product portfolio, applies in four scenarios:

1. GLP-1 era satiety adjunct — Bottin 2016 (PMID 27198187) + Turnbull 1993 (PMID 8257542)
2. Cardiometabolic chronic disease populations via the beta-glucan matrix — AnPro RCT diastolic BP reduction + beta-glucan series 13 RCTs
3. Plant-based athletes — Monteyne 2021 (PMID 33172506) + 2024 AnPro blend RCT
4. Sustainable supply chain options — fermentation-based ESG profile per section 2.6

This is the only brand mention in this guide, framed neutrally, sourced entirely from NC-quoted RCT evidence, and intended to inform rather than promote. Readers should compare ASXAN yeast protein products against alternative yeast protein sources on strain disclosure, processing methodology, and supplier Certificate of Analysis before purchase decisions.

3 · Regulatory background (single paragraph, not the focus)

From an international evidence-based hub perspective, the global regulatory status of yeast protein primarily references three frameworks. The US FDA recognizes Saccharomyces cerevisiae-derived products under longstanding Generally Recognized as Safe (GRAS) status (covering baker's yeast, brewer's yeast, and nutritional yeast), with yeast protein treated as a conventional food ingredient subject to standard 21 CFR allergen disclosure rules. The EU EFSA evaluates novel yeast protein products under Novel Food Regulation (EU) 2015/2283, with certain strains already authorized. China NMPA currently evaluates several yeast protein products as new food raw materials on an ongoing basis; consumers in mainland China should consult the NMPA official ingredient list for current authorization status. This international hub does not elaborate further on China-specific NMPA compliance; for Chinese market questions please consult NMPA official channels directly.

4 · How to read this guide for your situation (narrative use cases by Goal / Lifestyle)

If you are a resistance-trained athlete or active adult focused on muscle building

The evidence supports whey isolate at 1.6 g/kg/d distributed across 3 to 5 meals at 0.3 to 0.4 g/kg per meal, with each meal delivering at least 2.5 g of leucine. See Morton 2018 (PMID 28698222) and the Athletic Performance Goal page for personalized dosing. Plant-based athletes can match these outcomes with a yeast + pea + rice blend plus optional leucine fortification — see the Plant-Based Lifestyle and Athletic Performance Lifestyle pages.

If you are using a GLP-1 receptor agonist (semaglutide, tirzepatide, or related)

For weight management or type 2 diabetes, the evidence supports a whey preload (15 to 25 g before your largest meal) for incretin stimulation and lean mass preservation, paired with a yeast protein adjunct (25 to 30 g/d) for sustained satiety via the beta-glucan mechanism. See the GLP-1 Companion Goal and GLP-1 Companion Lifestyle pages, and always coordinate with your prescribing clinician.

If you are 60 years or older and concerned about muscle preservation or sarcopenia

The evidence-based triple stack is whey (20 to 25 g per meal) plus leucine (2.5 to 3 g per meal) plus vitamin D (800 IU/d), distributed across 3 main meals. See Bauer 2015 PROVIDE (PMID 26170041) and PROT-AGE (PMID 23867520) for the foundational evidence and the Senior 60+ Lifestyle page for fall-risk and frailty integration.

If your primary goal is weight management independent of GLP-1 RA use

Whey preload before the largest meal supports satiety and glycemic control (Pal 2010 PMID 20456814, Wirunsawanya 2018 PMID 29087242), and yeast protein provides complementary beta-glucan-mediated satiety. See the Weight Management Goal page for integrated protocols.

If your primary goal is cardiovascular health

Both whey (Whey2Go BP RCT, Pal 2010 BP RCT) and yeast (AnPro 8-week DBP reduction, beta-glucan immune series) carry evidence for blood pressure modulation through independent mechanisms. See the Heart Health Goal page for integrated cardiovascular nutrition guidance.

5 · Frequently Asked Questions

Ingredient deep dives

• Protein (cluster hub)
• Whey Protein
• Yeast Protein

Mechanism tags

DIAAS protein quality score (FAO 2013 framework · ileal digestibility gold standard) · PDCAAS → DIAAS framework upgrade (no truncation · per-EAA scoring) · Leucine threshold mTORC1 trigger (2.5-3 g per meal dose) · mTORC1 / S6K1 / 4E-BP1 protein synthesis signaling · MPS vs MPB net protein balance dynamics · Insulinotropic incretin response (whey-specific · GLP-1/GIP/CCK/PYY co-release) · Yeast cell wall β-glucan postprandial satiety + LDL-C lowering (matrix bonus) · Purified protein vs protein + functional matrix (whey purified vs yeast matrix)

Related Evidence Articles (peer)

• Omega-3 Evidence History — Cardiovascular, Inflammation and Beyond — shared GLP-1 companion + sarcopenia + cardiovascular framework; cross-read for omega-3 cluster relevance in the healthy-aging / muscle-preservation stack.
• 25 Years of NAD+ Clinical Evidence — adjacent healthy-aging stack chronology; cross-read for NAD-axis context complementing protein-cluster muscle-preservation strategy.

These peer evidence articles cover adjacent muscle-preservation / healthy-aging mechanisms. Cross-reading helps build a holistic protein + adjacent ingredient stack picture.